ライフサイエンスコーパス: neuropsychiatric

1 1 (CB1R) inhibitors, which are devoid of the neuropsychiatric adverse effects observed with brain-pen

2 Fewer participants experienced neuropsychiatric AEs on DOR than on EFV (25.0% vs 55.9%,

3 All participants underwent detailed neuropsychiatric and cognitive assessments, including te

4 s (NPS) that mimic the effects of controlled neuropsychiatric and illicit drugs have been forensicall

5 that appear to be selectively vulnerable to neuropsychiatric and neurodegenerative diseases, althoug

6 nd the alteration of these behaviors in many neuropsychiatric and neurodevelopmental disorders.

7 dence suggests that MECP2 may underlie other neuropsychiatric and neurological conditions, and perhap

8 may be a cross-diagnostic feature of several neuropsychiatric and neurological disorders in which dop

9 bitory neurotransmission balance and trigger neuropsychiatric and neurological disorders.

10 had a more complex phenotype with additional neuropsychiatric and/or developmental comorbidities.

11 vidence base for the treatment of cognitive, neuropsychiatric, and motor symptoms in patients with Le

12 sceptibility to autoimmune, cardiometabolic, neuropsychiatric, and neoplastic diseases.

13 Additional outcomes included any neuropsychiatric, anxiety, depressive, personality, or s

14 Using a comprehensive neuropsychiatric battery and a virtual casino to assess

15 In DIAN, lower neuropsychiatric burden and higher education were also a

16 In PREVENT-AD, lower neuroticism, neuropsychiatric burden, and higher education were assoc

17 d after removing de novo and known recurrent neuropsychiatric CNVs.

18 aco-resistant and 60% are affected by severe neuropsychiatric comorbid conditions, including impairme

19 tural properties which may be a biomarker of neuropsychiatric comorbidities of CD.

20 disorders in Parkinson's disease are common neuropsychiatric complications associated with dopamine

21 Autism Spectrum Disorder is a neuropsychiatric condition affecting 53 million children

22 Bipolar disorder is a chronic neuropsychiatric condition associated with mood instabil

23 Mania is a serious neuropsychiatric condition associated with significant m

24 eurological (conversion) disorder (FND) is a neuropsychiatric condition whereby individuals present w

25 20), and we observed novel correlations with neuropsychiatric conditions (P-values < 7.9 x 10-4).

26 effects of therapies for sleep disorders on neuropsychiatric conditions and also secondarily conside

27 connections between cognitive impairments in neuropsychiatric conditions and in the human population

28 Similarly, neuropsychiatric conditions and their treatments can aff

29 From the clinical perspective, a number of neuropsychiatric conditions are defined by the presence

30 arily considers the impacts of therapies for neuropsychiatric conditions on sleep.

31 To the extent that sleep problems affect neuropsychiatric conditions, it may be possible to addre

32 implicated in both PTSD and highly comorbid neuropsychiatric conditions, such as anxiety and depress

33 a commonly disrupted intracellular target in neuropsychiatric conditions, whether it be via alteratio

34 linked to gender differences across multiple neuropsychiatric conditions.

35 utic approaches for the treatment of diverse neuropsychiatric conditions.

36 n social memory are core components of these neuropsychiatric conditions.

37 ranging from animal models to patients with neuropsychiatric conditions.

38 roscience with relevance to a broad range of neuropsychiatric conditions.

39 rate greater than the general population in neuropsychiatric conditions.

40 choice in patients with sleep disorders and neuropsychiatric conditions.

41 otein; and maladaptive avoidance behavior in neuropsychiatric conditions.(2-5) Unlike fear, pathologi

42 ic factor (BDNF) have been linked to cancer, neuropsychiatric, diabetes, and gynecological disorders.

43 hypotheses derived from prior research into neuropsychiatric disease and cancer, gliomas may be expe

44 esults support the "dimensional" approach to neuropsychiatric disease classification and suggest pote

45 its functional significance in normative and neuropsychiatric disease models.

46 is population is exceptionally vulnerable to neuropsychiatric disease presentation during the hormona

47 Most neuropsychiatric disease risk variants are in noncoding

48 n reside in open chromatin, we reasoned that neuropsychiatric disease risk variants may affect chroma

49 traits ranging from Parkinson's disease and neuropsychiatric disease to cardiovascular and metabolic

50 y to developing schizophrenia, a devastating neuropsychiatric disease with high heritability but few

51 tal pathway and how its dysfunction leads to neuropsychiatric disease, we developed a method to conve

52 neural substrates for the pathophysiology of neuropsychiatric disease-associated cognitive dysfunctio

53 gion-specific mutations in Neurexin1alpha, a neuropsychiatric disease-associated synaptic molecule, i

54 ry synaptic plasticity and its relevance for neuropsychiatric disease.

55 ptome limits interpretation of risk loci for neuropsychiatric disease.

56 f the loop has been implicated previously in neuropsychiatric disease.

57 highly penetrant and common genetic cause of neuropsychiatric disease.

58 ssion tomography, mainly reflects gliosis in neuropsychiatric disease.

59 is critical for modeling, and understanding neuropsychiatric disease.

60 s and informing new treatment strategies for neuropsychiatric disease.

61 phenotypes associated with genetic forms of neuropsychiatric disease.

62 oup, with variable overlap between different neuropsychiatric diseases and heterogeneously expressed

63 erentiation, and its dysregulation can cause neuropsychiatric diseases and increase cancer severity.

64 understanding of the heterogeneous nature of neuropsychiatric diseases and overcome existing bottlene

65 orrelate with impulsive behaviour in several neuropsychiatric diseases and there is post-mortem evide

66 Motor stereotypies occurring in early-onset neuropsychiatric diseases are associated with dysregulat

67 in the SHANK3 human gene leads to different neuropsychiatric diseases including Autism Spectrum Diso

68 the contribution of genetic risk factors to neuropsychiatric diseases is limited to abnormal neurode

69 ommunications and/or have been implicated in neuropsychiatric diseases or cancer.

70 The etiologic pathways leading to neuropsychiatric diseases remain poorly defined.

71 k "attractors" could be a defining aspect of neuropsychiatric diseases such as schizophrenia, represe

72 Gliosis is common among neuropsychiatric diseases, but the relationship between

73 tion is characteristically impaired in major neuropsychiatric diseases, emphasizing its interest for

74 Defects in this circuitry are linked to neuropsychiatric diseases, including bipolar disorder, s

75 A role for microglia in neuropsychiatric diseases, including major depressive di

76 en recently linked to neurodevelopmental and neuropsychiatric diseases, suggesting a role for RNA reg

77 is axis in the treatment of inflammatory and neuropsychiatric diseases.

78 slational relevance of preclinical models of neuropsychiatric diseases.

79 alternations underlying human neurologic and neuropsychiatric diseases.

80 Tourette syndrome (TS) is a childhood-onset neuropsychiatric disorder characterized by repetitive mo

81 Chronic pain is a complex neuropsychiatric disorder characterized by sensory, cogn

82 Tourette syndrome (TS) is a neuropsychiatric disorder characterized by the occurrenc

83 A family history of any neuropsychiatric disorder was associated with poorer vis

84 -compulsive disorder (OCD) is a debilitating neuropsychiatric disorder with a genetic risk component,

85 Schizophrenia (SCZ) is a neuropsychiatric disorder with aberrant expression of mu

86 Tourette syndrome (TS) is a neuropsychiatric disorder with symptomatology that typic

87 e and epigenome, with disruptions in several neuropsychiatric disorder-associated pathways and gene f

88 isorder (ADHD) is a common, highly heritable neuropsychiatric disorder.

89 years, SD=11.40), of which 60 (19.7%) had a neuropsychiatric disorder.

90 ions, childhood epilepsy, and TSC-associated neuropsychiatric disorders (TANDs).

91 This work demonstrates increased rates of neuropsychiatric disorders [e.g., increased autism spect

92 around puberty are at the greatest risk for neuropsychiatric disorders across the lifespan.

93 ned aggression is characteristic of multiple neuropsychiatric disorders and can have various negative

94 to large datasets of >13,000 trios for five neuropsychiatric disorders and CHD.

95 has been implicated in a surprising range of neuropsychiatric disorders and cognitive and affective f

96 dings of human postmortem genomic studies of neuropsychiatric disorders and comparable animal models

97 Studies of neuropsychiatric disorders and congenital heart disease

98 based on large-scale GWAS data for different neuropsychiatric disorders and cortical brain measures,

99 fects in pathways previously associated with neuropsychiatric disorders and indications of interactio

100 ociations between T.gondii and various human neuropsychiatric disorders and outline how these may be

101 prenatal brain in susceptibility to various neuropsychiatric disorders and prioritize potential risk

102 creasingly associated with a wide variety of neuropsychiatric disorders and, more recently, causal fr

103 Neurodegenerative, neurodevelopmental and neuropsychiatric disorders are among the greatest public

104 Most neuropsychiatric disorders are highly polygenic, implica

105 atal immune activation increase the risk for neuropsychiatric disorders are unclear.

106 Conditional analysis reveals that distinct neuropsychiatric disorders associate with distinct sets

107 Pediatric autoimmune neuropsychiatric disorders associated with streptococcal

108 ovide potential targets for the treatment of neuropsychiatric disorders characterized by cognitive in

109 alanin has been implicated in stress-related neuropsychiatric disorders in humans and rodent models.

110 s its relationship to novel therapeutics for neuropsychiatric disorders in humans, and conclude by re

111 Neuropsychiatric disorders in patients and their familie

112 l affiliation are central features of severe neuropsychiatric disorders including autism spectrum dis

113 n being considered as a therapeutic for many neuropsychiatric disorders including depression, anxiety

114 le promise as a therapeutic intervention for neuropsychiatric disorders including depression, anxiety

115 s also associated with an increased risk for neuropsychiatric disorders including schizophrenia and a

116 could lead to novel treatment strategies for neuropsychiatric disorders involving OFC dysfunction.

117 ment and sex to impart risk for multifaceted neuropsychiatric disorders is also unlikely to be unders

118 nical studies indicate it is dysregulated in neuropsychiatric disorders like autism and addiction, ma

119 ns and have also been implicated in multiple neuropsychiatric disorders like fragile X syndrome, auti

120 des could explain the neurodevelopmental and neuropsychiatric disorders observed in mice and humans w

121 Neuropsychiatric disorders overlap in symptoms and share

122 ric history, medication or family history of neuropsychiatric disorders predicted cognitive and/or be

123 jority of common risk alleles identified for neuropsychiatric disorders reside in noncoding regions o

124 relationships, and test whether dystonia and neuropsychiatric disorders share a genetic relationship.

125 ompared with subcortical findings from other neuropsychiatric disorders studied by the ENIGMA consort

126 mber of the GPCR family and is implicated in neuropsychiatric disorders such as anxiety and depressio

127 rant genetic risk variants for developmental neuropsychiatric disorders such as schizophrenia (SCZ) a

128 is an important target for the treatment of neuropsychiatric disorders such as schizophrenia and Par

129 pregnancy increases the risk for developing neuropsychiatric disorders such as schizophrenia.

130 considerable progress has been made linking neuropsychiatric disorders to genetic underpinnings.

131 A family history of neuropsychiatric disorders was present in 36/231 (15.58%

132 es, from the synaptic to the behavioural, in neuropsychiatric disorders where decision-making biases

133 dical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic infl

134 ades the broad role of opioids in addiction, neuropsychiatric disorders, and pain states has been som

135 ship between ciliary protein dysfunction and neuropsychiatric disorders, for e.g. interconnections of

136 ns are implicated in the pathology of severe neuropsychiatric disorders, for which effective treatmen

137 3.3 microdeletion is associated with several neuropsychiatric disorders, including autism and schizop

138 as been considered a prospective therapy for neuropsychiatric disorders, including autism.

139 sregulation is a hallmark symptom of several neuropsychiatric disorders, including generalized anxiet

140 exposure towards increased vulnerability to neuropsychiatric disorders, including posttraumatic stre

141 (MIA) is a proposed risk factor for multiple neuropsychiatric disorders, including schizophrenia.

142 alience network (SN) is dysregulated in many neuropsychiatric disorders, including substance use diso

143 (MFC) centrally implicated in several major neuropsychiatric disorders, it is critical to understand

144 lap between MND, frontotemporal dementia and neuropsychiatric disorders, particularly mood disorders.

145 has been associated with a broad spectrum of neuropsychiatric disorders, prompting investigations int

146 ted in multiple human neurodevelopmental and neuropsychiatric disorders, such as autism, schizophreni

147 ation of the human brain serotonin system in neuropsychiatric disorders, such as major depression and

148 SULT4A1 has been implicated in several neuropsychiatric disorders, such as Phelan-McDermid synd

149 cated across multiple neurodevelopmental and neuropsychiatric disorders, there has been considerable

150 m of severity in striatal dysfunction across neuropsychiatric disorders, where dysfunction was most s

151 rms an important framework for understanding neuropsychiatric disorders, which are proposed to be the

152 e results have implications for treatment of neuropsychiatric disorders, which may be characterized b

153 Dysregulation of inhibition can lead to neuropsychiatric disorders, yet little is known about th

154 this approach to GWAS data from two related neuropsychiatric disorders-autism spectrum disorder and

155 he treatment of affective and stress-related neuropsychiatric disorders.

156 tion, and its dysfunction is associated with neuropsychiatric disorders.

157 to further our etiological understanding of neuropsychiatric disorders.

158 and a therapeutic lead for the treatment of neuropsychiatric disorders.

159 erplay between blunted empathic behavior and neuropsychiatric disorders.

160 to improve our mechanistic understanding of neuropsychiatric disorders.

161 thickness in previously published studies of neuropsychiatric disorders.

162 s its genetic and biological relationship to neuropsychiatric disorders.

163 ave identified numerous loci associated with neuropsychiatric disorders.

164 tic agents for treatment of ciliopathies and neuropsychiatric disorders.

165 r disorder, and its overlap with other major neuropsychiatric disorders.

166 sychiatric, medication and family history of neuropsychiatric disorders.

167 TS are complex and often overlap with other neuropsychiatric disorders.

168 rebrain development, including signatures of neuropsychiatric disorders.

169 ormal function and significantly impaired in neuropsychiatric disorders.

170 itive processing that characterizes numerous neuropsychiatric disorders.

171 AT), and is implicated in several DA-related neuropsychiatric disorders.

172 A-dependent processes including a variety of neuropsychiatric disorders.

173 tion and elucidating striatal dysfunction in neuropsychiatric disorders.

174 eceptor hypofunction associated with certain neuropsychiatric disorders.

175 ABAergic neuron gene expression and multiple neuropsychiatric disorders.

176 ary to improve treatments for stress-related neuropsychiatric disorders.

177 ions (CNVs) that predispose to developmental neuropsychiatric disorders.

178 2 and associated to several neurological and neuropsychiatric disorders.

179 sts with myriad symptoms, including multiple neuropsychiatric disorders.

180 ns marked by deficient inhibition, including neuropsychiatric disorders.

181 nce of deleterious variants segregating with neuropsychiatric disorders.

182 en implicated in developmentally originating neuropsychiatric disorders.

183 e involved in the pathophysiology of several neuropsychiatric disorders.

184 Akt1/3 mutant mice in behaviors relevant to neuropsychiatric disorders.

185 rphology are known in neurodevelopmental and neuropsychiatric disorders.

186 tive drugs for the treatment of a variety of neuropsychiatric disorders.

187 ing, while DG dysfunction is associated with neuropsychiatric disorders.

188 y in genes whose dysregulation is related to neuropsychiatric disorders.

189 iptome is now a phenotypic signature of many neuropsychiatric disorders.

190 s have been viewed as symptoms of associated neuropsychiatric disorders.

191 l oxytocinergic targets for the treatment of neuropsychiatric disorders.

192 ioid receptor (KOR) is implicated in various neuropsychiatric disorders.

193 foresight and is symptomatic of a number of neuropsychiatric disorders.

194 ng and quantification of synaptic density in neuropsychiatric disorders.

195 at are elicited by these drugs used to treat neuropsychiatric disorders.

196 ened risks for the subsequent development of neuropsychiatric disorders.

197 observed in a wide range of neurological and neuropsychiatric disorders.

198 cium channels, are often mutated in multiple neuropsychiatric disorders.

199 Oxytocin may have promise as a treatment for neuropsychiatric disorders.

200 rogate this network in preclinical models of neuropsychiatric disorders.

201 genetic variations that are associated with neuropsychiatric disorders.

202 or the treatment of symptoms associated with neuropsychiatric disorders.

203 potential targets for improving treatment of neuropsychiatric disorders.

204 re effective brain stimulation therapies for neuropsychiatric disorders.

205 and their dysfunction associates with severe neuropsychiatric disorders.

206 es across patients diagnosed with four major neuropsychiatric disorders: autism spectrum condition (A

207 idered as a promising therapeutic target for neuropsychiatric disorders; its pharmacology, however, r

208 be used to predict the incidence of adverse neuropsychiatric effects.

209 well as stress-related and stress-inducible neuropsychiatric endophenotypes in both man and mouse.

210 ular and behavioral abnormalities resembling neuropsychiatric endophenotypes.

211 choice of initial monotherapy and continuous neuropsychiatric evaluation of affected children.

212 Our findings indicate that neuropsychiatric features are common in FTLD and form an

213 Lower neuroticism and neuropsychiatric features, along with higher measures of

214 e current clinical guidelines, together with neuropsychiatric features, such as hallucinations and de

215 sentation at single symptom level, including neuropsychiatric features.

216 n-based study, we aimed to determine whether neuropsychiatric history, medication or family history o

217 Thus, the association of neuropsychiatric illness to environmental chemical expos

218 nfection is associated with neurological and neuropsychiatric illness.

219 sleep are extremely common in patients with neuropsychiatric illness.

220 n or autoimmune disease is a risk factor for neuropsychiatric illness.

221 preclinical (basic neuroscience) studies of neuropsychiatric illness.

222 s for sleep disorders have direct effects on neuropsychiatric illnesses that may be unrelated to thei

223 and have a positive impact on the course of neuropsychiatric illnesses.

224 nges in brain function, such as epilepsy and neuropsychiatric illnesses.

225 , idiopathic schizophrenia, and other severe neuropsychiatric illnesses.

226 findings identify a mechanistic substrate of neuropsychiatric impairment after STN-DBS and suggest th

227 a chronic syndrome of recurrent seizures and neuropsychiatric impairment as well as inflammation of l

228 splasia and other symptoms of MAS, including neuropsychiatric impairments, are associated with increa

229 iveness and disinhibition as assessed by the neuropsychiatric instruments.

230 The Neuropsychiatric International Consortium for Frontotemp

231 red, fully structured, or Mini International Neuropsychiatric Interview (MINI) diagnostic interviews

232 ression assessed with the Mini International Neuropsychiatric Interview depression module, taking ant

233 ADNC/LATE-NC was associated with lower total Neuropsychiatric Inventory and agitation factor scores t

234 Longitudinal Neuropsychiatric Inventory and psychotropic medication p

235 onal/behaviour symptoms as assessed with the Neuropsychiatric Inventory questionnaire or across neuro

236 among others, gastrointestinal symptoms and neuropsychiatric manifestations.

237 2-0.87 for cognitive measures, 0.31-0.91 for neuropsychiatric measures).

238 Data were extracted on patient neuropsychiatric, medication and family history of neuro

239 nd likely measures of neurological sequelae: neuropsychiatric morbidities, educational landmarks, use

240 r in risk for other cancer or mucocutaneous, neuropsychiatric, or musculoskeletal AEs.

241 lationship impacts cognitive development and neuropsychiatric outcomes in this age group.

242 into mechanisms linking maternal health with neuropsychiatric outcomes of children.

243 more important determinant of postoperative neuropsychiatric outcomes than preoperative brain struct

244 ise as a pure form of reactive inhibition in neuropsychiatric patients displaying inhibitory deficits

245 cal dataset acquired from the Consortium for Neuropsychiatric Phenomics, we further demonstrated that

246 ie some of the heterogeneity observed in the neuropsychiatric phenotype.

247 Neuropsychiatric phenotypes have long been known to be i

248 cation syndrome, a disorder characterized by neuropsychiatric phenotypes including hyperactivity and

249 ons, which predispose carriers to a range of neuropsychiatric phenotypes.

250 mutations in elucidating the pathogenesis of neuropsychiatric phenotypes.

251 isidentification syndromes occur commonly in neuropsychiatric practice and can be explained through a

252 ests by severe cardiomyopathy, myopathy, and neuropsychiatric problems.

253 heir relation to several pathways related to neuropsychiatric processes, and to drug targets.

254 Recently the similarity of neuropsychiatric profiles across a range of functional s

255 ahydrocannabinol (THC) is linked to elevated neuropsychiatric risk and induces neuronal, molecular an

256 Mutations in the neuropsychiatric risk gene CACNA1C, which encodes the Ca

257 ns in glutamatergic neurons are enriched for neuropsychiatric risk variants, particularly those assoc

258 ASoC as a functional mechanism of noncoding neuropsychiatric risk variants, providing a powerful fra

259 longitudinal study of adverse post-traumatic neuropsychiatric sequelae (APNS) among participants seek

260 Adverse posttraumatic neuropsychiatric sequelae (APNS) are common among civili

261 tantial subset develop adverse posttraumatic neuropsychiatric sequelae (APNS) such as posttraumatic s

262 tures can improve the diagnosis of long-term neuropsychiatric sequelae of mTBI.

263 se targeted to the brain, which may underlie neuropsychiatric sequelae, a considerable cause of posts

264 l stimulation titration in the prevention of neuropsychiatric side-effects after STN-DBS.

265 y of life, but can be complicated by adverse neuropsychiatric side-effects, including impulsivity.

266 ntia present with a wide range of cognitive, neuropsychiatric, sleep, motor, and autonomic symptoms.

267 om the altered nodes revealed an overlapping neuropsychiatric spectrum extending from MDD on one end,

268 ggest potential novel drug targets along the neuropsychiatric spectrum.

269 elect the optimal time window in healthy and neuropsychiatric subjects.

270 changes (LATE-NC) is associated with greater neuropsychiatric symptom burden, compared to either path

271 he relationship between diagnostic group and neuropsychiatric symptom burden.

272 mer's disease is not associated with greater neuropsychiatric symptom burden.

273 nestic MCI, suggesting that anxiety may be a neuropsychiatric symptom of Alzheimer's disease (AD) pat

274 shared and distinct mechanisms that mediate neuropsychiatric symptoms across disorders, e.g. 22q11.2

275 he perturbations that drive the emergence of neuropsychiatric symptoms and experiences.

276 Preclinical mutation carriers exhibited neuropsychiatric symptoms compared with non-carriers tha

277 ork localization of clinical, cognitive, and neuropsychiatric symptoms in Alzheimer's disease', by Te

278 isk' patients be identified prior to DBS; do neuropsychiatric symptoms relate to the distribution of

279 ions as a promising approach to the study of neuropsychiatric symptoms such as anxiety in cognitively

280 method to localize clinical, cognitive, and neuropsychiatric symptoms to brain networks, providing i

281 trum disorder (ASD) encompasses wide-ranging neuropsychiatric symptoms with unclear etiology.

282 ed which combinations of personality traits, neuropsychiatric symptoms, and cognitive lifestyle (year

283 ogy with combinations of personality traits, neuropsychiatric symptoms, and cognitive lifestyle.

284 Streptococcus (GAS) infections that lead to neuropsychiatric symptoms.

285 ia should include the presence and nature of neuropsychiatric symptoms.

286 lain why many CNVs affect a similar range of neuropsychiatric symptoms.

287 ording to the disease stage along with other neuropsychiatric symptoms.

288 of normal behaviour, or deficits underlying neuropsychiatric symptoms.

289 ium-phosphate deposition and associated with neuropsychiatric symptoms.

290 king; patient function, quality of life, and neuropsychiatric symptoms; caregiver burden and well-bei

291 hrenia is a common, chronic and debilitating neuropsychiatric syndrome affecting tens of millions of

292 -mediated disease characterized by a complex neuropsychiatric syndrome in association with an antibod

293 early intervention efforts in this disabling neuropsychiatric syndrome.

294 eron alpha, two proposed causative agents in neuropsychiatric systemic lupus erythematosus (NPSLE).

295 We administered formal neuropsychiatric testing (Alzheimer Disease Research Cen

296 controls) completed a single study visit for neuropsychiatric testing and phlebotomy.

297 POCD is a decline in neuropsychiatric tests scores from presurgical baseline

298 tic correlations between left-handedness and neuropsychiatric traits, including schizophrenia and bip

299 ory responses as translational biomarkers in neuropsychiatric treatment development.

300 iscuss the intersection of the findings from neuropsychiatric treatments and homeostatic plasticity s